Beginning Testing for a Lung Transplant

Beginning Testing for a Lung Transplant

About six weeks ago, I shared that I am under consideration by the University of California, San Francisco (UCSF) for a lung transplant. A few weeks ago, I got the good news that UCSF said YES to allow me to start initial testing to…

Real-World Data Support Use of Ofev in IPF Management, Study Finds

Real-world data shows that treatment with Ofev (nintedanib, marketed by Boehringer Ingelheim) helps stabilize idiopathic pulmonary fibrosis (IPF) and is well-tolerated, a German study reports. The research, “Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis,” was published in the journal Respiration. Ofev and…

Fibrosis Treatment Candidate IBIO-CFB03 to Be Further Developed, iBio Announces

IBIO-CFB03, an investigational fibrotic therapy, was selected as iBio’s lead candidate for further development, the company announced in a press release. The product may be a new treatment option for idiopathic pulmonary fibrosis (IPF) and scleroderma. Fibrosis is characterized by inflammation and buildup of collagen…

To My Manager: What I Wish You Knew

Working with a life-threatening illness such as idiopathic pulmonary fibrosis (IPF) is difficult to manage, regardless of whether that work is full- or part-time. Exhaustion, illness, and hospitalizations often get in the way of being able to complete tasks efficiently, and may also prevent me from meeting organizational deadlines.

HGE Health Extends Telemedicine Service to Pulmonary Fibrosis Patients

HGE Health of Philadelphia is partnering with the Temple Lung Center to offer a telemedicine disease management program for idiopathic pulmonary fibrosis (IPF) patients in the United States and elsewhere. The healthcare technology company already has a similar program for patients with chronic obstructive pulmonary disease, or COPD. The Temple Lung Center, part…